Motavizumab, RSV, and subsequent wheezing - Authors' reply. - <a href="../public/authorSummary-O'Brien, Katherine L.do">Katherine L O'Brien</a>, <a href="../public/authorSummary-Driscoll, Amanda J.do">Amanda J Driscoll</a>, <a href="../public/authorSummary-Santosham, Mathuram.do">Mathuram Santosham</a>, <a href="../public/authorSummary-Hammitt, Laura L.do">Laura L Hammitt</a>, <a href="../public/authorSummary-Karron, Ruth A.do">Ruth A Karron</a>

Motavizumab, RSV, and subsequent wheezing - Authors' reply.

Authors	Katherine L O'Brien, Amanda J Driscoll, Mathuram Santosham, Laura L Hammitt, Ruth A Karron
Journal	The Lancet. Infectious diseases (Lancet Infect Dis) Vol. 16 Issue 12 Pg. 1329-1330 (12 2016) ISSN: 1474-4457 [Electronic] United States
PMID	27998592 (Publication Type: Letter, Comment)
Chemical References	Antibodies, Monoclonal, Humanized motavizumab
Topics	Antibodies, Monoclonal, Humanized Humans Infant Respiratory Sounds Respiratory Syncytial Virus Infections

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!